3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Conditions
Brain Neoplasms
6
Prostatic Neoplasms
5
Glioma
2
Glioblastoma
2
Disease
2
Urinary Bladder Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Interventions
Blood Specimen Collection
6
pembrolizumab
2
fluciclovine F-18
2
Surveys and Questionnaires
2
Preoperative Exercise
2
Magnetic Resonance Imaging
2
Exercise
2
Cryosurgery
2
Bevacizumab
2
tislelizumab
1
neratinib
1
imetelstat
1
daratumumab
1
atezolizumab
1
abiraterone
1
Waiting Lists
1
Videotape Recording
1
Urine Specimen Collection
1
Triamcinolone Acetonide
1
Transcutaneous Electric Nerve Stimulation
1
Tomography, X-Ray Computed
1
Thoracic Surgical Procedures
1
TIC10 compound
1
Sulfonylurea Compounds
1
Standard of Care
1
Specimen Handling
1
Sodium-Glucose Transporter 2 Inhibitors
1
Serologic Tests
1
Sequence Analysis, RNA
1
S-Adenosylmethionine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Disease
×
fluciclovine F-18
×
1 year
×
Clear all
NCT04410133
2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3
Completed
151 enrolled
29 charts
NCT04410367
2025-07-20
PURSUE
Blue Earth Diagnostics
Phase 2
Completed
23 enrolled
10 charts